This company has been marked as potentially delisted and may not be actively trading. OTCMKTS:AGYTF Allergy Therapeutics (AGYTF) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisHeadlinesBuy This Stock About Allergy Therapeutics Stock (OTCMKTS:AGYTF) 30 days 90 days 365 days Advanced Chart Get Allergy Therapeutics alerts:Sign Up Key Stats Today's Range$0.09▼$0.0950-Day Range N/A52-Week Range$0.17▼$0.19VolumeN/AAverage VolumeN/AMarket Capitalization$58.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Acarovac MPL, Venomil, Synbiotics, Penicillin Diagnostics, and Peanut. The company also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom. Read More Receive AGYTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allergy Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AGYTF Stock News HeadlinesInvestors in Allergy Therapeutics (LON:AGY) have seen impressive returns of 143% over the past yearMay 5, 2025 | finance.yahoo.comAllergy Therapeutics grants options to key managementFebruary 14, 2025 | msn.comYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.July 15 at 2:00 AM | Priority Gold (Ad)Allergy Therapeutics Shows Promising Results for Peanut AllergyDecember 5, 2024 | markets.businessinsider.comAllergy Therapeutics Begins Innovative Paediatric Allergy TrialNovember 27, 2024 | markets.businessinsider.com3 Best Drawing Exercises to Improve Your Art (DYNAMIC LINES INSTANTLY- AT ANY LEVEL!)November 1, 2024 | msn.comWhy are food allergies on the rise?October 31, 2024 | bbc.co.ukSNEAKING INTO MY POOL AT 3AM ON A SCHOOL NIGHT **Again**October 30, 2024 | msn.comSee More Headlines Company Calendar Today7/15/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED-DRUGS Sub-IndustryN/A Current SymbolOTCMKTS:AGYTF Previous SymbolNASDAQ:AGYTF CIKN/A Webwww.allergytherapeutics.com Phone44-19-0384-4700FaxN/AEmployees600Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$69.51 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book8.50Miscellaneous Outstanding SharesN/AFree FloatN/AMarket Cap$58.56 million OptionableNot Optionable Beta648.10 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (OTCMKTS:AGYTF) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allergy Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Allergy Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
